Supplementary Figures 1 - 4 from ERK and AKT Signaling Drive MED1 Overexpression in Prostate Cancer in Association with Elevated Proliferation and Tumorigenicity
posted on 2023-04-03, 16:07authored byFeng Jin, Shazia Irshad, Wei Yu, Madesh Belakavadi, Marina Chekmareva, Michael M. Ittmann, Cory Abate-Shen, Joseph D. Fondell
PDF file - 529K, Fig. S1. MED1 antibody specificity. Fig. S2. Anti-phospho-MED1 antibody specificity. Fig. S3. Inhibition of ERK or AKT signaling decreases MED1 phosphorylation and expression in prostate cancer cells. Fig. S4. Phospho-MED1 binds to the androgen receptor in prostate cancer cells.